Radio–Tartaglia syndrome: disease-characteristics research report

Radio–Tartaglia syndrome (RATARS; MONDO:0859143) is a rare, autosomal-dominant, SPEN-related neurodevelopmental disorder. Its best-established molecular cause is a heterozygous truncating SPEN variant consistent with haploinsufficiency. Developmental and speech delay, intellectual disability, hypotonia, behavioral differences, and variable congenital anomalies define the clinical picture. The principal human evidence remains a study of 34 affected individuals from 33 families; consequently, many frequencies below are observations among assessed people, not population estimates. [63][27][16][2]

Evidence convention. “Human” denotes affected-person observations; “mouse,” “fly,” and “in vitro” denote experimental evidence that must not be treated as proof of the corresponding mechanism or treatment effect in patients. Percentages retain their published denominators. This is an aggregated disease-level report, not an individual-patient EHR extract. [16][31]

1. Disease information and identifiers

In the foundational paper’s abstract, the authors describe “34 individuals with truncating variants in SPEN” and a disorder overlapping proximal 1p36 deletion syndrome (Radio et al., electronically published 16 February 2021, PMID 33596411, DOI 10.1016/j.ajhg.2021.01.015). [45][16]

2. Etiology, risks, protection, and gene–environment interaction

3. Phenotypes

How to read the table: “Frequency” is the count among people evaluated for that feature in the original 34-person cohort, as tabulated in the 2024 Korean case comparison. A later case does not change those original denominators. Proposed HPO labels/IDs are annotation suggestions, not a claim that each has been independently validated as a syndrome-specific association. Most developmental findings arise in infancy or childhood; cohort-wide, feature-specific severity and progression were generally not measured. Functional impacts are clinical implications, not measured EQ-5D, SF-36, or PROMIS results. [31][16]

Frequency caution: the 2024 comparison reports 8/29 CHD, whereas the original cohort’s broader cardiac-features/CHD table reports 14/22. Those are different ascertainment and phenotype definitions, not evidence that the underlying heart-defect rate changed. Likewise, syndrome-page percentages without clear denominators should not replace the primary study counts. [31][16]

4. Genetic and molecular information

SPEN (HGNC:17575; NCBI Gene:23013; OMIM:613484) encodes a nuclear transcriptional repressor also called SHARP/MINT. It has RNA-recognition motifs and a C-terminal SPOC region involved in corepressor interactions. Disease-associated variants in the foundational series are germline-consistent heterozygous stop-gain or frameshift variants; fibroblast testing in three people supported a non-blood-restricted origin. The reported variants were absent from the gnomAD dataset examined at publication, which must not be interpreted as a newly verified 2026 allele frequency. [44][16][27]

5. Environmental and infectious information

No infectious agent, toxic exposure, radiation exposure, occupational hazard, or lifestyle behavior is established as a cause or trigger of RATARS. The disease’s genetic cause should not be confused with factors that can influence general health or with the experimental Spen–diet effects observed in flies. Consequently, CTD-style chemical–disease causation, a pathogen taxon, and a disease-preventive CHEBI exposure should not be populated without new evidence. [27][119]

6. Mechanism and pathophysiology

Ordered causal chain

1. Initiating lesion: A germline heterozygous truncating SPEN variant leads to predicted reduced functional SPEN dosage; the aggregate genetic evidence supports haploinsufficiency, although variant-by-variant protein loss was not measured in the original patients. [27][16]
2. Upstream molecular branch—transcription: Reduced SPEN is inferred to lead to altered recruitment or action of transcriptional corepressors during development. SPEN’s transcription-repressor function is experimentally supported, but the exact disrupted developmental targets in RATARS patients have not been established. [44][132]
3. Epigenetic/X-chromosome branch: Reduced SPEN leads to an observed, female-specific blood X-chromosome DNA-methylation episignature. Its relationship to silencing of particular genes in patients, and to their individual symptoms, remains inferred. [16]
4. Experimental explanation of that branch: In cellular and mouse systems, XIST/Xist RNA recruits SPEN/SHARP, which promotes corepressor/HDAC3-dependent chromatin repression and X-linked gene silencing. Whether altered X inactivation itself causes the full RATARS phenotype is not demonstrated. [46][47][54]
5. Neurodevelopmental branch: Perturbed developmental gene regulation is inferred to result in altered nervous-system development and neuronal maintenance, leading to developmental, motor, speech, cognitive, and behavioral manifestations. Human clinical associations and mouse neural-knockout phenotypes support this chain, but its intermediate human cell types and target genes remain unresolved. [16][92]
6. Additional organ branches: Altered developmental transcription is inferred to contribute to congenital cardiac and other structural findings; separate altered energy regulation might contribute to later obesity. The cardiac-development and fat-metabolism mechanisms derive chiefly from mouse and fly models, respectively, and are not demonstrated patient-level causal chains. [92][100][16]

Mechanistic detail and annotation suggestions

There is no established RATARS-specific patient proteomic, metabolomic, lipidomic, spatial-transcriptomic, single-cell atlas, multi-omics integration, or CRISPR-screen signature. The human developmental single-cell data above are expression-context analyses, not single-cell sequencing of affected patients. No primary evidence supports adding ischemia, fibrosis, chronic inflammation, apoptosis, mTOR, PI3K–AKT, or mitochondrial enzyme deficiency as a demonstrated RATARS mechanism. [16][54]

7. Anatomical structures affected

8. Temporal development

Onset is developmental: hypotonia and feeding problems can be apparent in infancy, while speech, learning, behavior, and some structural findings become apparent as the child grows. In the foundational series, ages at last assessment ranged from fetal life to 24 years 6 months. Increased BMI tended to emerge after about age four. These observations do not establish formal early/intermediate/end-stage categories or a common progressive neurological course. [16]

A Korean boy’s longitudinal case illustrates variability rather than a universal trajectory: axial hypotonia was present in infancy; at 28 months developmental testing showed substantial delays; at five years he could walk with support and combine two words. The study’s abstract describes his diagnosis as resulting from “whole genome sequencing” (Kim et al., published online 16 December 2024, DOI 10.26815/acn.2024.00717). No standardized remission pattern, disease duration estimate beyond its developmental nature, or validated critical treatment window has been published. [31]

9. Inheritance and population

10. Diagnostics

The diagnostic anchor is molecular identification and interpretation of a plausible heterozygous SPEN loss-of-function variant in the appropriate clinical setting. Phenotypic findings alone are insufficiently specific to separate RATARS from 1p36 deletion syndrome or other neurodevelopmental disorders. [27][31][34]

11. Outcome and prognosis

Survival probability, mortality rate, life expectancy, and validated prognostic biomarkers are unknown. The original series included individuals assessed into young adulthood, but its ascertainment and follow-up cannot generate a survival estimate. Developmental, speech, behavioral, mobility, feeding, cardiac, and sometimes weight-related needs contribute to morbidity; no disease-specific EQ-5D, SF-36, or PROMIS results, formal disability distribution, or reliable treatment-response rate were established in the cited cohort. Variant location did not yield a clear severity predictor. Recovery probabilities, including a treated-versus-untreated comparison, are unavailable. [16][27]

Potential complications should be recorded patient by patient, not assumed: for example, aspiration and poor growth in the Korean child required substantial feeding support. The original cohort observed seizures in only 3/32, so epilepsy should not be represented as inevitable or as a demonstrated major mortality cause. [31][16]

12. Treatment and real-world implementation

There is no demonstrated disease-modifying treatment for RATARS. Care is individualized around documented developmental and organ-specific needs; the interventions below are management suggestions or reported care, not syndrome-specific efficacy claims. No RATARS drug-response rates, pharmacogenomic rule, approved gene/RNA/cell therapy, immunotherapy, or RATARS-specific NCT trial was established in the reviewed evidence. Suggested NCIT intervention labels are provided for knowledge-base matching; NCIT codes require independent terminology verification. [16][31]

13. Prevention and counseling

Primary prevention of a spontaneous de novo SPEN variant is not known. No vaccine, antimicrobial prophylaxis, toxin-avoidance program, or lifestyle change prevents RATARS. Genetics-led counseling can explain autosomal-dominant transmission, the distinction between de novo and inherited variants, and reproductive options after a familial variant is established; a de novo result does not by itself quantify possible parental germline mosaicism. Targeted familial testing and, where desired, reproductive testing are individualized options, not population screening. [27][31]

Secondary and tertiary prevention means recognizing developmental and organ-specific issues early and addressing complications—for example, aspiration or a clinically important cardiac defect—rather than preventing the genetic disorder itself. There is no validated RATARS risk score, prophylactic medication, or disease-specific public-health/environmental intervention. [16][31]

14. Other species and natural disease

15. Model organisms and model limitations

Knowledge-base priority: enter the SPEN–RATARS loss-of-function association and the denominator-qualified human phenotypes as established; label the X-chromosome methylation signature as a female-biased research biomarker; and keep Notch, neural-cell-specific, and fatty-acid-metabolism explanations tagged to their experimental evidence type rather than asserting them as proven patient mechanisms. [16][31][47][100]

Reference Validation

Checked with linkml-reference-validator 0.3.0.

Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

• DOI:10.1371/journal.pgen.1008333&type=printable (2 mentions) - Identifier did not resolve to a record

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, Gene, OMIM, Taxon, MGI.

13 of 23 terms resolved to a current term; the rest could not be looked up either way.